|Publication number||US7384428 B2|
|Application number||US 10/668,241|
|Publication date||Jun 10, 2008|
|Filing date||Sep 24, 2003|
|Priority date||Mar 22, 2000|
|Also published as||CA2331050A1, CA2331050C, CN1314193A, DE10106376A1, DE10106376B4, DE60111882D1, DE60111882T2, EP1138278A1, EP1138278B1, US6736838, US20040062788, WO2001070298A2, WO2001070298A3|
|Publication number||10668241, 668241, US 7384428 B2, US 7384428B2, US-B2-7384428, US7384428 B2, US7384428B2|
|Original Assignee||Medinol, Ltd.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (31), Referenced by (3), Classifications (18), Legal Events (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a divisional of application Ser. No. 09/532,653, filed Mar. 22, 2000 now U.S Pat. No. 6,736,838.
The present invention relates generally to stents for implanting into a living body. In particular, the present invention relates to a biological covering for a stent suitable for implanting into a variety of lumens.
In an attempt to prevent restenosis, metallic vascular stents have been permanently implanted in coronary or peripheral vasculature. These stents are typically delivered intraluminally by a catheter and expanded in place to support a diseased portion of an artery.
One shortcoming of these conventional stents is that even after stent implantation, restenosis can still occur. Another shortcoming is that during the implantation of the stent, the stent may cause particles to discharge from the artery wall through the open cell. These dislodged particles can embolize in the bloodstream, and may cause catastrophic effects.
In an attempt to reduce these problems, coverings have been proposed for stents. These coverings have been made from artificial materials, such as PTFE. As of yet, however, coverings made from artificial materials have not proven successful. This may be because of the poor biocompatibility of such materials.
There is also some experience using biological tissue such as bovine pericardium to build a covering for a stent that is more biocompatible than coverings made from artificial materials. Preliminary results with bovine pericardium have been encouraging from the point of view of biocompatibility.
The current method, however, of creating a covering using biological tissue is simplistic. A rectangular piece of pericardium is harvested from a bovine source. The pericardium is then, after being prepared so that it is suitable for implantation, rolled into a cylinder. The abutting edges of the pericardium are sewn together to create a covering. This covering is then placed over a stent.
There is an inherent disadvantage in this cut and sew approach to creating a covering. Biological tissue has a very small expansion range. Therefore, the diameter of the cut and sewn cylinder of tissue is limited to a very small range. This limits the stent to a very small range of expansion diameters, limiting the utility of the stent. This also limits the difference in diameter between the stent as delivered and the stent at its expanded state, increasing significantly the profile of the delivery system required for a given supported diameter.
In one embodiment of the present invention, biological fibers or biodegradable fibers or fiber groups are arranged as interwoven threads to make an expandable tube. The interwoven threads are arranged with an acute angle between the interwoven threads while the stent is unexpanded. When the stent is expanded, the angle between the interwoven threads increases. This allows the stent covering to be expanded to a variety of diameters.
In another embodiment, a strip of pericardium is helically wound around a stent with a substantial overlap between adjacent windings while the stent is in a first, unexpanded diameter. During expansion to a second expanded diameter, the strips will slide over the stent and unwrap for a smaller number of loops, but will still completely cover the stents. In a further enhancement to this embodiment, the edges of the spiral wrapping are formed into locking folds to prevent the spiral loops from separating during expansion of the stent and covering.
Accordingly, it is an object of the current invention to provide an improved biological tissue covering for a stent, and a method for producing the same.
Further objectives and advantages of the subject invention will be apparent to those skilled in the art from the detailed description of the disclosed invention.
The subject invention will now be described in detail for specific preferred embodiments of the invention, it being understood that these embodiments are intended only as illustrative examples and the invention is not to be limited thereto.
The stent has a covering 24 formed of biological fibers. The biological fibers may be obtained by dissolving any suitable biological tissue, such as bovine, ovine, or porcine pericardium tissue. Alternatively, the fibers can be formed from other material, such as Cut-Gut collagen threads.
As shown in
Typically, the endoprostheses will be implanted using a conventional balloon angioplasty procedure. In this procedure, the stent 22 and associated covering 24 are placed onto the balloon at the end of a balloon catheter and delivered to the site of the restricted or diseased portion of an artery. The stent and covering are then expanded into contact with the lumen by inflating the balloon. The catheter can then be deflated and withdrawn, leaving the stent and covering at the treatment site. As shown in
Another embodiment of the biological stent covering is shown in
Upon expansion of the stent from the diameter D to D′, the helically wound strip of pericardium unwinds. However, because of the overlap between adjacent strips, no area of the stent is uncovered during and after expansion of the stent and covering. The ratio between the maximal expanded diameter without causing gaps, and that of the unexpanded stent equals the overlap ratio of the stent.
An alternative embodiment of the spiral wrapped stent is shown in
The strip with the interlocking edges is helically wound around the stent in the same manner as described above with respect to the embodiment illustrated in
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4755593||Jul 24, 1986||Jul 5, 1988||Lauren Mark D||Novel biomaterial of cross-linked peritoneal tissue|
|US5037377||Aug 21, 1986||Aug 6, 1991||Medtronic, Inc.||Means for improving biocompatibility of implants, particularly of vascular grafts|
|US5376110||Jun 9, 1993||Dec 27, 1994||Baxter International Inc.||Method of manufacturing pliable biological grafts materials|
|US5510077||Sep 15, 1994||Apr 23, 1996||Dinh; Thomas Q.||Method of making an intraluminal stent|
|US5554182||Apr 27, 1995||Sep 10, 1996||Medtronic, Inc.||Method for preventing restenosis|
|US5571166||Sep 15, 1994||Nov 5, 1996||Medtronic, Inc.||Method of making an intraluminal stent|
|US5575818||Feb 14, 1995||Nov 19, 1996||Corvita Corporation||Endovascular stent with locking ring|
|US5591224||Sep 15, 1994||Jan 7, 1997||Medtronic, Inc.||Bioelastomeric stent|
|US5595571||Apr 18, 1994||Jan 21, 1997||Hancock Jaffe Laboratories||Biological material pre-fixation treatment|
|US5628785||Apr 27, 1995||May 13, 1997||Medtronic, Inc.||Bioelastomeric stent|
|US5653747||Oct 20, 1995||Aug 5, 1997||Corvita Corporation||Luminal graft endoprostheses and manufacture thereof|
|US5693085||Apr 26, 1995||Dec 2, 1997||Scimed Life Systems, Inc.||Stent with collagen|
|US5718159||Apr 30, 1996||Feb 17, 1998||Schneider (Usa) Inc.||Process for manufacturing three-dimensional braided covered stent|
|US5718973||Jul 26, 1995||Feb 17, 1998||W. L. Gore & Associates, Inc.||Tubular intraluminal graft|
|US5720777||May 16, 1995||Feb 24, 1998||Hancock Jaffee Laboratories||Biological material pre-fixation treatment|
|US5800507||Apr 27, 1995||Sep 1, 1998||Medtronic, Inc.||Intraluminal stent|
|US5843158||Feb 6, 1996||Dec 1, 1998||Medtronic, Inc.||Limited expansion endoluminal prostheses and methods for their use|
|US5843180||Jan 17, 1997||Dec 1, 1998||Hancock Jaffe Laboratories||Method of treating a mammal having a defective heart valve|
|US5843181||Jan 17, 1997||Dec 1, 1998||Hancock Jaffe Laboratories||Biological material pre-fixation treatment|
|US5849034||Apr 27, 1995||Dec 15, 1998||Medtronic, Inc.||Intraluminal stent|
|US5865723||Dec 29, 1995||Feb 2, 1999||Ramus Medical Technologies||Method and apparatus for forming vascular prostheses|
|US5895407||Jan 19, 1998||Apr 20, 1999||Jayaraman; Swaminathan||Microporous covered stents and method of coating|
|US6156062||Dec 3, 1997||Dec 5, 2000||Ave Connaught||Helically wrapped interlocking stent|
|US6187039||Dec 10, 1997||Feb 13, 2001||Purdue Research Foundation||Tubular submucosal graft constructs|
|US6254627||Sep 17, 1998||Jul 3, 2001||Diseno Y Desarrollo Medico S.A. De C.V.||Non-thrombogenic stent jacket|
|DE29917306U1||Oct 1, 1999||Mar 9, 2000||Bio Vascular Inc||Stent-Hülle|
|EP0328401A1||Feb 10, 1989||Aug 16, 1989||Unisearch Limited||Anastomosis augmentation device|
|WO1995029647A2||Apr 26, 1995||Nov 9, 1995||Scimed Life Systems, Inc.||Stent with collagen|
|WO1997025002A1||Jan 3, 1997||Jul 17, 1997||Medtronic, Inc.||Expansible endoluminal prostheses|
|WO1999015105A1||Sep 21, 1998||Apr 1, 1999||Freidberg Carlos Vonderwalde||Non-thrombogenic stent jacket|
|WO2000033768A1||Dec 4, 1998||Jun 15, 2000||Bio-Vascular, Inc.||Stent cover|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US9205177||Feb 26, 2010||Dec 8, 2015||Peytant Solutions, Inc.||Stents modified with material comprising amnion tissue and corresponding processes|
|US20070288081 *||May 10, 2007||Dec 13, 2007||Abbott Laboratories||Stent delivery system having a stent stopper|
|US20100228335 *||Feb 26, 2010||Sep 9, 2010||John Schorgl||Stents modified with material comprising amnion tissue and corresponding processes|
|U.S. Classification||623/1.44, 606/108|
|International Classification||A61F2/90, A61L31/08, A61F2/24, A61M5/00, A61L27/28, A61M29/00, A61L31/00|
|Cooperative Classification||A61L31/08, A61F2/07, A61L31/005, A61F2002/075, A61F2/90|
|European Classification||A61F2/07, A61L31/00F, A61F2/90, A61L31/08|
|Mar 28, 2006||AS||Assignment|
Owner name: MEDINOL LTD., ISRAEL
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZULI HOLDINGS, LTD.;REEL/FRAME:017730/0304
Effective date: 20060323
|Jan 23, 2012||REMI||Maintenance fee reminder mailed|
|Jun 10, 2012||LAPS||Lapse for failure to pay maintenance fees|
|Jul 31, 2012||FP||Expired due to failure to pay maintenance fee|
Effective date: 20120610